While the extra dose — of either Pfizer of Moderna vaccine — seemed to have some effect, rates of infection in the study were not substantially different to those who had three doses of Pfizer, the study official said.
Gili Regev-Yochay, a lead investigator on the study, told reporters that "the vaccine is excellent against the Alpha and Delta," but the study found that "for Omicron, it's not good enough," The Times of Israel reported Monday evening.
The investigator did not release data from the trial, noting that the results are preliminary. But she said she shared the early findings as there was a large public interest.
(... ) Business Insider / Times of Israel
